{"id":"isosorbide-dinitrate-hydralazine","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Headache"},{"rate":"10-20","effect":"Dizziness"},{"rate":"5-15","effect":"Hypotension"},{"rate":"5-10","effect":"Palpitations"},{"rate":"5-10","effect":"Lupus-like syndrome (hydralazine)"},{"rate":"5-10","effect":"Tachycardia"}]},"_chembl":null,"_fixedAt":"2026-03-30T14:06:37.378575","_dailymed":{"setId":"e1e63cd5-d1e4-4af5-bad5-1ad41ea46b00","title":"BIDIL (HYDRALAZINE HYDROCHLORIDE AND ISOSORBIDE DINITRATE) TABLET, FILM COATED [AZURITY PHARMACEUTICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Isosorbide dinitrate is a nitrate that releases nitric oxide, causing vasodilation and reducing venous return (preload). Hydralazine is an arteriolar vasodilator that reduces peripheral vascular resistance (afterload). This combination is particularly effective in heart failure by reducing the workload on the heart while improving coronary perfusion.","oneSentence":"Isosorbide dinitrate provides nitric oxide to relax blood vessels, while hydralazine directly relaxes vascular smooth muscle, together reducing cardiac preload and afterload to improve heart function.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:56:54.263Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction, particularly in African American patients"},{"name":"Angina pectoris"}]},"_fixedFields":["pubmed(39)"],"trialDetails":[{"nctId":"NCT02627196","phase":"NA","title":"Baroreflex Activation Therapy for Heart Failure","status":"COMPLETED","sponsor":"CVRx, Inc.","startDate":"2016-04-19","conditions":"Heart Failure","enrollment":1090},{"nctId":"NCT03514108","phase":"PHASE4","title":"DANHEART (H-HeFT and Met-HeFT)","status":"COMPLETED","sponsor":"Henrik Wiggers","startDate":"2018-03-01","conditions":"Heart Failure, Diabetes","enrollment":1100},{"nctId":"NCT01471834","phase":"NA","title":"Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"CVRx, Inc.","startDate":"2011-06","conditions":"High Blood Pressure","enrollment":40},{"nctId":"NCT06400784","phase":"PHASE4","title":"Hypertensive Heart Failure Treatment in SSA","status":"COMPLETED","sponsor":"University of Abuja","startDate":"2022-03-25","conditions":"A Feasibility Study on Hypertensive Heart Failure Treatment","enrollment":50},{"nctId":"NCT06218199","phase":"PHASE4","title":"Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts","status":"RECRUITING","sponsor":"Heart Center Research, LLC","startDate":"2021-07-08","conditions":"Heart Failure, Congestive","enrollment":80},{"nctId":"NCT02305095","phase":"","title":"Genomic Response Analysis of Heart Failure Therapy in African Americans","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2015-05-01","conditions":"Heart Failure","enrollment":225},{"nctId":"NCT01516346","phase":"PHASE2","title":"Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction","status":"COMPLETED","sponsor":"Corporal Michael J. Crescenz VA Medical Center","startDate":"2012-01","conditions":"Heart Failure, Congestive Heart Failure","enrollment":44},{"nctId":"NCT02228408","phase":"PHASE4","title":"Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-08-28","conditions":"Chronic Hemodialysis (ESRD)","enrollment":17},{"nctId":"NCT04206865","phase":"PHASE4","title":"Comparison of ARNI to Alternate Oral Vasodilator Therapies in Patients With Low Cardiac Output","status":"WITHDRAWN","sponsor":"The Cleveland Clinic","startDate":"2019-11-25","conditions":"Cardiogenic Shock","enrollment":""},{"nctId":"NCT01720160","phase":"NA","title":"BAROSTIM® Hope for Heart Failure Study","status":"UNKNOWN","sponsor":"CVRx, Inc.","startDate":"2012-11","conditions":"Heart Failure","enrollment":98},{"nctId":"NCT02522208","phase":"PHASE1","title":"Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2015-09","conditions":"Heart Failure","enrollment":12},{"nctId":"NCT01822808","phase":"PHASE3","title":"Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure","status":"UNKNOWN","sponsor":"University of Cape Town","startDate":"2013-01","conditions":"Acute Heart Failure, Left Ventricular Dysfunction","enrollment":500},{"nctId":"NCT01587313","phase":"PHASE1","title":"A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2012-04","conditions":"Healthy","enrollment":36},{"nctId":"NCT02343393","phase":"PHASE3","title":"Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2015-01","conditions":"Cardio-Renal Syndrome","enrollment":100},{"nctId":"NCT00047775","phase":"PHASE4","title":"African-American Heart Failure Trial","status":"COMPLETED","sponsor":"Nitromed","startDate":"2001-05","conditions":"Congestive Heart Failure","enrollment":1100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":39,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Isosorbide Dinitrate + Hydralazine","genericName":"Isosorbide Dinitrate + Hydralazine","companyName":"Corporal Michael J. Crescenz VA Medical Center","companyId":"corporal-michael-j-crescenz-va-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Isosorbide dinitrate provides nitric oxide to relax blood vessels, while hydralazine directly relaxes vascular smooth muscle, together reducing cardiac preload and afterload to improve heart function. Used for Heart failure with reduced ejection fraction, particularly in African American patients, Angina pectoris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}